MARKET

SIGY

SIGY

Sigyn Therapeutics Inc
OTCPK
0.039
NaN%
Closed 09:30 05/26 EDT
OPEN
--
PREV CLOSE
0.039
HIGH
--
LOW
--
VOLUME
--
TURNOVER
--
52 WEEK HIGH
19.20
52 WEEK LOW
0.011
MARKET CAP
62.61K
P/E (TTM)
-0.0194
1D
5D
1M
3M
1Y
5Y
1D
Oragenics Q1 net loss narrows 0.71% to $2.2 million
PUBT · 05/08 20:05
Oragenics Signs LOI To License Certain Disease Indications Of CardioDialysis, Blood Purification Technology, From Sigyn Therapeutics
Benzinga · 05/07 12:34
ORAGENICS INC - TO RECEIVE EXCLUSIVE LICENSE FOR CARDIODIALYSIS FOR TBI AND NEURODEGENERATIVE DISEASES
Reuters · 05/07 12:30
ORAGENICS INC - TO ISSUE 3.25 MLN RESTRICTED PREFERRED SHARES TO SIGYN, CONVERTIBLE ONE-TO-ONE
Reuters · 05/07 12:30
Oragenics signs LOI to license Sigyn CardioDialysis technology for TBI treatment
PUBT · 05/07 12:16
Sigyn Therapeutics Delays Annual SEC Filing
TipRanks · 04/01 01:45
Sigyn Therapeutics delays annual report filing, cites time constraints on required disclosures
Reuters · 03/31 21:22
Signet Jewelers Introduces FY27 Guidance
NASDAQ · 03/19 12:36
More
About SIGY
Sigyn Therapeutics, Inc. develops medical devices to treat cancer and infectious disease disorders. The Company's lead therapeutic candidate, Sigyn Therapy, is a broad-spectrum blood purification technology designed to treat pathogen-associated inflammatory disorders. Candidate treatment indications include endotoxemia and inflammation in end-stage renal disease (dialysis) patients, sepsis (a cause of hospital deaths), community-acquired pneumonia (a cause of death among infectious diseases), and emerging pandemic threats. Sigyn Therapy is a single-use disposable device that is deployable on the global infrastructure of hemodialysis and continuous renal replacement therapy machines. Its development pipeline includes a cancer treatment system comprised of ChemoPrep to enhance the tumor site delivery of chemotherapy, and ChemoPure to reduce treatment toxicity and inhibit the spread of cancer metastasis. Its ImmunePrep platform enhances the performance of immunotherapeutic antibodies.

Webull offers Sigyn Therapeutics Inc stock information, including OTCPK: SIGY real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, SIGY stock news, and many more online research tools to help you make informed decisions. Trade stocks for 0 commission and 0 contract fees on the web version for easy and convenient access, or download the Webull app and trade on the go.

You can practice and explore trading SIGY stock methods without spending real money on the virtual paper trading platform.